Sirtex wins $1.3m Start grant
Thursday, 28 October, 2004
Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.
Targeted Hyperthermia Therapy uses the company's microsphere platform technology to deliver magnetic nanoparticles to tumours, followed by treatment with an alternating magnetic field to heat up the tumour causing death of the cancer cells.
The company has recently overcome some technical issues regarding the scale up of the treatment from animals to humans.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
